Cantourage Further Expands Its Leading Market Position: Premium Producer LOT420 Receives EU-GMP Certification

Cantourage Group SE

/ Key word(s): Alliance/Statement

Cantourage Further Expands Its Leading Market Position: Premium Producer LOT420 Receives EU-GMP Certification

29.10.2026 / 10:23 CET/CEST

The issuer is solely responsible for the content of this announcement.


  • EU-GMP certification for craft cannabis producer: LOT420 is among the most sought-after suppliers in the European medical cannabis market.
  • Shorter delivery times, fresher products: LOT420’s cannabis flowers will reach European pharmacies even faster in the future.
  • Strategic competitive advantage: With the EU-GMP certification of another established premium producer, Cantourage strengthens its access to high-demand products and further consolidates its position in the European market.

Cantourage Group SE (hereinafter “Cantourage”, ISIN: DE000A3DSV01) and Canadian cannabis producer LOT420 are deepening their partnership following LOT420’s successful EU-GMP certification. Cantourage once again supported the certification process as sponsor and will benefit from exclusive access to LOT420’s popular cannabis products in Europe for the coming years. Following the successful EU-GMP certification of cultivation partner Green Karat just a few weeks ago, this latest milestone further demonstrates Cantourage’s regulatory expertise and strengthens its supply chain across the company’s European target markets.

Based southeast of Montreal, LOT420 is an established premium supplier in the European medical cannabis market. The producer specializes in high-quality craft cannabis, focusing on small-batch cultivation of non-irradiated cannabis flowers and cultivation techniques refined over many years. Cantourage first introduced LOT420’s products to the European market in 2023, where the company has since established itself as one of the most respected brands in the medical cannabis sector.

With LOT420’s EU-GMP certification, Cantourage is further strengthening its value chain and creating additional opportunities for importing dried cannabis flowers from Canada. As a result, LOT420’s premium flowers will be able to reach European pharmacies even faster after harvest. At the same time, shifting processing steps to EU-GMP-certified cultivation partners enables a more efficient cost structure, additional capacity and reduced operational risks. Cantourage is thus further expanding its position as a strategic partner for international premium producers seeking access to the European market.

“Together with us, LOT420 has become another long-standing partner to successfully achieve EU-GMP certification. The strong demand for LOT420’s products demonstrates just how important access to high-quality brands and products is to our market position. At the same time, by supporting our partners in obtaining certification, we are laying the foundation for more efficient supply chains, regulatory stability and further growth. This is another clear validation of our business model of enabling international cannabis producers to enter the European market as their regulatory and commercial partner,” says Philip Schetter, CEO of Cantourage Group SE.

Cantourage remains committed to systematically expanding its international network of EU-GMP-certified premium producers. The combination of strong partnerships, regulatory expertise and an increasingly flexible supply chain provides a solid foundation for further strengthening the company’s competitive position in Europe.

About Cantourage

Cantourage is a leading European company engaged in the production and distribution of medical cannabis preparations and cannabis-based pharmaceuticals. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to access the growing European medical cannabis market faster, more easily and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In doing so, Cantourage consistently ensures compliance with the highest European pharmaceutical quality standards. The Company offers pharmaceutical-grade products across all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on 11 November 2022 – DE000A3DSV01 (ISIN).

 

 


29.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Cantourage Group SE
Feurigstraße 54
10827 Berlin
Germany
E-mail: info@cantourage.com
Internet: https://www.cantourage.com/
ISIN: DE000A3DSV01
WKN: A3DSV0
Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate BSX
LEI Code: 3912003NCTLO6YHA9V48
EQS News ID: 2424552

 
End of News EQS News Service

2424552  29.10.2026 CET/CEST

Evotec SE to Announce Results for the First Nine Months 2026 on November 5, 2026

Evotec SE

/ Key word(s): Miscellaneous

Evotec SE to Announce Results for the First Nine Months 2026 on November 5, 2026

29.10.2026 / 07:30 CET/CEST

The issuer is solely responsible for the content of this announcement.


Hamburg, Germany, October 29, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) will hold a webcast and conference call to announce its financial results for the first nine months 2026 and provide a business update on Thursday, November 5, 2026. The conference call will be held in English.

Webcast details

Date:  Thursday, November 5, 2026

Time:  2.00 pm CET (1.00 pm GMT, 8.00 am EST)

To join the audio webcast and to access the presentation slides, please register via this link.

The on-demand version of the webcast will be available on our website: www.evotec.com.

Conference call details

To join the conference call, please pre-register via this link. You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.

A simultaneous slide presentation for participants dialing in via phone is available under this link.

 

About Evotec SE

Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec’s global team of around 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.

 

Forward-looking statements

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

 

Investor Relations and Media Contact

Dr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.com

 


29.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard), Tradegate BSX; Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; Nasdaq
LEI Code: 529900F9KI6OYITO9B12
EQS News ID: 2422664

 
End of News EQS News Service

2422664  29.10.2026 CET/CEST

Drägerwerk AG & Co. KGaA: Dräger with higher net sales and earnings in the first nine months of 2026

Drägerwerk AG & Co. KGaA

/ Key word(s): Quarterly / Interim Statement/Quarter Results

Drägerwerk AG & Co. KGaA: Dräger with higher net sales and earnings in the first nine months of 2026

29.10.2026 / 07:30 CET/CEST

The issuer is solely responsible for the content of this announcement.


Dräger with higher net sales and earnings in the first nine months of 2026

  • Order intake noticeably increased
  • Net sales growth in both divisions
  • EBIT increased by almost half – positive one-off effects from customs refunds

Lübeck – Drägerwerk AG & Co. KGaA increased its order intake by approximately EUR 79 million to around EUR 2,674 million in the first nine months of 2026 (9 months 2025: EUR 2,594.1 million). Net sales rose by approximately EUR 110 million to around EUR 2,454 million (9 months 2025: EUR 2,343.5 million). Earnings before interest and taxes (EBIT) went up by approximately EUR 35 million to EUR 111.8 million (9 months 2025: EUR 77.1 million). The EBIT margin improved to 4.6 percent (9 months 2025: 3.3 percent). EBIT included one-off effects from customs refunds.

“Demand for our ‘Technology for Life’ increased noticeably in the first nine months of 2026, and net sales also rose sharply. Earnings before interest and taxes were significantly above the prior-year level – due to the refund of U.S. customs paid in the prior year, but also thanks to the strong operating performance,” says Stefan Dräger, Chairman of the Executive Board of Drägerwerk Verwaltungs AG. “We are confident that we will achieve our annual targets.”

Order intake continues to rise
Group order intake rose by 3.6 percent (net of currency effects) to EUR 2,673.5 million in the first nine months of 2026 (9 months 2025: EUR 2,594.1 million). Germany was the largest growth driver, with a significant increase of around 15 percent. Demand also grew in the Europe, Middle East, and Africa (EMEA) and Asia-Pacific (APAC) regions. The Americas region recorded a decline. The main reason for this was the high prior-year level: In the second quarter of 2025, Dräger had received a major order for hospital infrastructure systems from Mexico.

In the medical division, order intake decreased by 3.5 percent (net of currency effects) to EUR 1,430.7 million (9 months 2025: EUR 1,495.5 million). Excluding the major order in the prior year, it would have remained almost stable (net of currency effects).

In the safety division, order intake increased significantly by 13.1 percent (net of currency effects) to EUR 1,242.8 million (9 months 2025: EUR 1,098.6 million). All regions and all product areas contributed to this development.

Strong net sales growth in both divisions
Group net sales increased by 5.3 percent (net of currency effects) to EUR 2,453.9 million in the first nine months of 2026 (9 months 2025: EUR 2,343.5 million). In the medical division, net sales increased by 4.4 percent (net of currency effects) to EUR 1,367.0 million (9 months 2025: EUR 1,322.3 million). In the safety division, net sales increased by 6.5 percent (net of currency effects) to EUR 1,087.0 million (9 months 2025: EUR 1,021.2 million).

Earnings significantly above the prior year
EBIT rose by almost half to EUR 111.8 million (9 months 2025: EUR 77.1 million). The EBIT margin also improved significantly by 1.3 percentage points to 4.6 percent (9 months 2025: 3.3 percent).

EBIT for the first nine months included one-off effects of EUR 27.9 million from customs refunds. Of this amount, EUR 7.8 million was attributable to the second quarter and EUR 20.1 million to the third quarter. Part of these refunds – a total of EUR 3.8 million – relates to customs expenses from the current fiscal year and is therefore earnings-neutral. At the same time, customs expenses of EUR 25.8 million were incurred in the U.S. in the current year, which are nonrefundable under current law.

The gross margin benefited from the customs refunds by around one percentage point. It increased by 1.7 percentage points to 46.8 percent (9 months 2025: 45.1 percent). Functional expenses in the first nine months of 2026 were 5.6 percent higher than the prior-year figure. The main drivers were personnel, logistics, and IT costs.

Business performance in the third quarter
In the third quarter, order intake increased by 7.0 percent (net of currency effects) to EUR 926.2 million (Q3 2025: EUR 856.1 million). The medical division recorded a decline of 3.0 percent (net of currency effects) to EUR 474.3 million (Q3 2025: EUR 484.7 million) due to weaker demand in the EMEA region. Demand in the Middle East declined significantly due to the ongoing Iran conflict. In the safety division, order intake increased by 20.2 percent (net of currency effects) to EUR 451.9 million (Q3 2025: EUR 371.4 million), thanks to good performance in all regions. Germany was the largest driver, with above-proportional growth of around 59 percent (net of currency effects), due in particular to a major order in the defense business.

Dräger’s net sales rose by 1.0 percent (net of currency effects) to EUR 850.8 million (Q3 2025: EUR 833.3 million). The gross margin increased by 1.8 percentage points to 47.5 percent (Q3 2025: 45.6 percent). EBIT came to EUR 48.0 million (Q3 2025: EUR 56.7 million). The EBIT margin amounted to around 5.6 percent (Q3 2025: 6.8 percent).

Forecast for 2026
For the current fiscal year, Dräger continues to expect an increase in net sales of 2.0 to 6.0 percent (net of currency effects) and an EBIT margin of 6.0 to 8.0 percent.

Further information is available in the financial report at www.draeger.com.

Disclaimer
This press release contains statements on the future development of Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to date. They were compiled to the best of the company’s knowledge. Dräger does not provide any warranty nor assume any responsibility for the future developments and results described above. These are dependent on a number of factors. They entail various risks and contingencies outside of the company’s influence and are based on assumptions which could prove to be incorrect. Dräger does not assume any responsibility for updating the forward-looking statements contained in this report. This does not infringe any legal stipulations on the adjustment of forecasts. Information on the financial indicators used (incl. alternative performance measures) can be found on our corporate website www.draeger.com in our Investor Relations section.

 

Key figures for the first nine months
(€ million)
9M 2026 9M 2025 Change Net of cur-
rency effects
         
Order intake 2,673.5 2,594.1 +3.1 +3.6
Germany 673.5 587.8 +14.6 +14.6
Europe, Middle East, and Africa 1,048.5 1,030.4 +1.7 +1.5
Americas 555.0 591.6 -6.2 -5.4
Asia-Pacific 396.5 384.4 +3.2 +6.0
         
Order intake, medical division 1,430.7 1,495.5 -4.3 -3.5
Order intake, safety division 1,242.8 1,098.6 +13.1 +13.1
         
Net sales 2,453.9 2,343.5 +4.7 +5.3
Germany 588.5 559.7 +5.2 +5.2
Europe, Middle East, and Africa 997.8 926.5 +7.7 +7.5
Americas 521.7 492.8 +5.9 +7.0
Asia-Pacific 345.9 364.6 -5.1 -2.3
         
Net sales, medical division 1,367.0 1,322.3 +3.4 +4.4
Net sales, safety division 1,087.0 1,021.2 +6.4 +6.5
         
EBIT 111.8 77.1    
EBIT margin 4.6 3.3    
Earnings after income taxes 73.8 45.5    
         
EBIT margin, medical division -0.7 -1.7    
EBIT margin, safety division 11.2 9.8    
         
Employees 16,716 16,684    
         
         
Key figures for the third quarter
(€ million)
Q3 2026 Q3 2025 Change Net of cur-
rency effects
         
Order intake 926.2 856.1 +8.2 +7.0
Germany 258.0 199.8 +29.1 +29.1
Europe, Middle East, and Africa 336.3 352.9 -4.7 -5.4
Americas 194.1 180.3 +7.6 +4.5
Asia-Pacific 137.9 123.1 +12.0 +10.5
         
Order intake, medical division 474.3 484.7 -2.2 -3.0
Order intake, safety division 451.9 371.4 +21.7 +20.2
         
Net sales 850.8 833.3 +2.1 +1.0
Germany 206.6 195.4 +5.7 +5.7
Europe, Middle East, and Africa 351.3 334.9 +4.9 +4.2
Americas 170.0 181.8 -6.5 -9.5
Asia-Pacific 122.9 121.1 +1.5 +0.3
         
Net sales, medical division 469.4 471.3 -0.4 -1.4
Net sales, safety division 381.3 362.0 +5.3 +4.1
         
EBIT 48.0 56.7    
EBIT margin 5.6 6.8    
Earnings after income taxes 33.6 35.9    
         
EBIT margin, medical division 1.0 2.3    
EBIT margin, safety division 11.4 12.6    
         
Employees 16,716 16,684    

 


29.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Drägerwerk AG & Co. KGaA
Moislinger Allee 53-55
23558 Lübeck
Germany
Phone: +49 (0)451 882-0
Fax: +49 (0)451 882-2080
E-mail: info@draeger.com
Internet: www.draeger.com
ISIN: DE0005550602, DE0005550636 (Vorzugsaktien)
WKN: 555060, 555063 (Vorzugsaktien)
Indices: SDAX, TecDax
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX; London, Aquis, Stockholm, BX, SIX, Vienna Stock Exchange
LEI Code: 5493005UFVHY0PPNKD75
EQS News ID: 2424128

 
End of News EQS News Service

2424128  29.10.2026 CET/CEST

BioVersys announces first patient first visit in Phase 2b RIV-CARE trial of BV100

 

Basel, Switzerland. October 29, 2026, 7am CEST

  • BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP) and bloodstream infections (BSI) caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC).
  • RIV-CARE (NCT07431307), an open label Phase 2b clinical trial, aims to compare BV100 plus low-dose polymyxin B plus ceftazidime/avibactam, or plus cefiderocol to best-available-therapy (BAT) in multiple geographies with very high drug resistance levels.
  • RIV-CARE complements the ongoing Phase 3 RIV-TARGET trial of BV100, and is expected to broaden evidence based treatment in clinical practices, ahead of potential commercialisation.
  • RIV-CARE is conducted by ADVANCE-ID clinical trial network with funding support from Wellcome
  • Interim read-out is expected in H1 2027.

BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced today the first patient first visit in RIV-CARE, an open label Phase 2b differentiation trial of BV100.

RIV-CARE will enrol approximately 100 patients with suspected or confirmed hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP) and bloodstream infections (BSI) caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC). RIV-CARE aims to compare BV100 plus low-dose polymyxin B in combination with different background antibiotics (ceftazidime/avibactam or Cefiderocol) versus best available therapy across multiple geographies, to provide real-world evidence of clinical practice in settings with very high levels of drug resistance.

Dr. Glenn E Dale, Chief Development Officer of BioVersys: “CRABC remains amongst the most difficult to treat bacterial pathogens in hospitalized patients, with mortality reaching up to 50% globally due to very limited treatment options. Our RIV-CARE study allows us to bring a promising and novel treatment option, BV100, to patients who need it most. Importantly, RIV-CARE allows us to generate evidence exactly in settings with the highest resistance and greatest need.”

Professor David Paterson, Director of ADVANCE-ID, said: “Half of people with serious CRAB infections will die. Doctors desperately need new antibiotic options for treating these infections so we can lower the death rate. We hope that the RIV-CARE trial will help determine if BV100 plus low-dose polymyxin B is a safe and effective option for these infections.”

The last patient enrolled is anticipated towards end of 2027. RIV-CARE is conducted by the ADVANCE-ID clinical trial network, thanks to the generous contribution of Wellcome with SGD 22 million (c. USD 17m or CHF 14m). The non-dilutive funding from Wellcome offsets approximately 2/3 of the trial cost.

Dr. Florian von Groote-Bidlingmaier, Head of Clinical Research, Infectious Disease at Wellcome, said: “Antimicrobial resistance remains an urgent global health threat, and accelerating the development of new antibiotics into clinical use is a high priority. Partnerships like the one for this trial, that bring together industry, academia, clinical expertise and philanthropy, are vital for accelerating antibiotic R&D. The enrolment of the first patient in RIV-CARE is an important milestone, and it is exciting a potential new treatment is being evaluated in settings and communities already bearing a high burden of drug resistance.”

In September 2026, BV100 was granted Fast Track Designation by the US FDA, under the Qualified Infectious Disease Product (QIDP) Designation received in 2019. These designations make BV100 eligible for priority FDA review, increased communication on clinical trial design and data requirements, and a five-year extension of market exclusivity in the US.

BV100 is currently being studied in two clinical trials: the pivotal Phase 3 global registration trial, RIV-TARGET, which announced first patient first visit in April 2026, and the open-label Phase 2b differentiation trial, RIV-CARE. First submissions for regulatory approval are anticipated by mid-2028.

Dr. Marc Gitzinger, Chief Executive Officer of BioVersys, said: “We are pleased to report first patient first visit in RIV-CARE, our Phase 2b differentiation trial which is now recruiting in parallel with our RIV-TARGET Phase 3 trial. Together, RIV-TARGET and RIV-CARE represent a focused dual-trial strategy intended to support both regulatory approval and future commercial uptake of BV100. RIV-Target will deliver the pivotal data for registration, while RIV-CARE is designed to help answer the questions physicians will ask at the bed side, providing evidence on how BV100 performs in comparison with best available therapies in multiple geographies. The interim analysis of RIV-CARE, anticipated for H1 2027, will provide an important early read-out.”

RIV-CARE Phase 2b study design

RIV-CARE aims to evaluate the safety and efficacy of BV100 in combination with low dose polymyxin B plus ceftazidime/avibactam or cefiderocol in patients with suspected or confirmed CRABC nosocomial pneumonia (VABP and HABP) and BSI of non-urinary tract origin. This is an open-label study, and therefore, no blinding will be done.

The study is divided into two parts (Part A and Part B), recruiting in parallel. Approximately 90 patients will be recruited in Part A, and approximately 10 subjects will be recruited in Part B, with enrolment ending once Part A enrolment is complete.

In Part A, patients will be randomized 1:1:1, to one of the three treatment groups until the CRABC m-MITT population includes 30 evaluable subjects per group:

  • Group 1: 300 mg BV100 in combination with 500,000 IU (50 mg) polymyxin B infused over 2 hours every 12 hours (q12h), plus 2 g/0.5 g ceftazidime/avibactam, infused over 2 hours every 8 hours (q8h).
  • Group 2: 300 mg BV100 in combination with 500,000 IU (50 mg) polymyxin B infused over 2 hours every 12 hours (q12h), plus 2 g cefiderocol infused over 3 hours every 8 hours (q8h).
  • Group 3: Best Available Therapy, which is determined by the site for each individual patient according to local epidemiology and the patient’s antibiotic history.

Part B is a prospective multicentre, open label, non-randomized, additional single cohort to evaluate the PK, safety, and efficacy BV100 in combination with both low dose polymyxin B and cefiderocol in patients with CRABC ventriculitis or meningitis. After 14 days of treatment with BV100 and low dose polymyxin B, the BV100 therapy must be stopped, but patients may continue therapy with cefiderocol and best available additional therapy at the discretion of the investigator and as needed.

This study follows the successful completion of a Phase II study that showed that BV100 plus polymyxin B halved all-cause mortality compared with best available therapy, meaning 28-day mortality of 25% compared to 28-day mortality of 60% in best available therapy. In vitro, the combination of BV100 with low-dose polymyxin B and cefiderocol showed synergy and a reduction in the emergence of resistance, suggesting improved treatment outcomes in patients.

NVision Unveils First Manufacturable Molecular Qubit, Breakthrough Validated in Peer-Reviewed Nature Paper

NVision Quantum

/ Key word(s): Miscellaneous

NVision Unveils First Manufacturable Molecular Qubit, Breakthrough Validated in Peer-Reviewed Nature Paper

28.10.2026 / 17:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


NVision Unveils First Manufacturable Molecular Qubit, Breakthrough Validated in Peer-Reviewed Nature Paper

Partners with HyperLight to integrate thin-film molecular qubits onto advanced photonic integrated circuits, paving the way for a new architecture that delivers quantum computing at scale

Summary:

  • Announces publication of landmark peer-reviewed research in Nature validating the first individually addressable organic molecular qubit with photonic interface.
  • Advances a quantum computing architecture that combines compatibility with standard silicon foundry manufacturing with photonic connectivity to enable quantum computing at scale.
  • Establishes a strategic partnership with HyperLight to integrate thin-film molecular qubits directly onto advanced photonic integrated circuits. 

ULM, Germany – October 28, 2026 – NVision, a quantum technology company, announced the publication of landmark peer-reviewed research in Nature and a strategic partnership with HyperLight Corporation (“HyperLight”), an industry leader in thin-film lithium niobate (TFLN) photonics. The companies will integrate NVision’s thin-film molecular qubits directly onto advanced photonic integrated circuits (PICs). Together, these milestones establish a practical path to quantum computing at scale, using photonic connectivity to link quantum resources within and across processors. This opens a path toward millions of qubits on chips compatible with standard foundry manufacturing.

The Nature publication, A Single-Molecule Spin-Photon Interface, confirms the first ever individually addressable organic molecular spin-photon interface, which is the key ingredient for connecting stationary qubits with photons. Until now, molecular spins could not be individually and coherently controlled, preventing them from serving as true qubits. That barrier has now been broken: the core building block can be controlled at the single-molecule level. This opens a new path to scale, where molecular qubits can be deposited as thin films, much like OLED materials, directly on top of PICs, turning established photonic chip technology into a platform for scaling quantum computers.

“This proves what we’ve long believed: that organic chemistry offers a fundamentally better building block for quantum,” said Dr. Sella Brosh, CEO of NVision. “For years, the industry has been locked in a hardware race using modalities that would require decades and multi-billion-dollar proprietary fabrication facilities to achieve scale. With the creation of the world’s first manufacturable organic qubit, we now enter quantum’s molecular era, establishing a new architecture based on photonic connectivity from the get-go, with a clear path to scale through existing foundry infrastructure.”

Alongside the Nature publication, NVision announced a strategic partnership with HyperLight, a global leader in TFLN electro-optic PICs for high-bandwidth environments such as AI data centers, telecom and metro networks. The collaboration will integrate NVision’s molecular qubits as a thin film that can be deposited directly onto photonic chips, extending HyperLight’s TFLN Chiplet™ technology further into quantum applications. 

“Integrating NVision’s breakthrough molecular qubits onto our PICs unlocks a compelling path for scalable quantum hardware while showcasing the capabilities and versatility of HyperLight’s TFLN technology,” said Kevin Luke, co-founder and Head of Custom Development at HyperLight. “Photonic interconnectivity is essential for scaling quantum processors, and combining our optical chip infrastructure with manufacturable molecular thin films allows us to deliver high-density, chip-scale quantum connectivity that leverages decades of investment in semiconductor fabrication.”

The milestone directly advances NVision’s Photonic Integrated Quantum Circuits (PIQC) platform from foundational physics into commercial hardware development. Following initial chip deliveries from foundry partners, NVision is targeting a live demonstration of on-chip performance on PICs by the end of 2026. The company’s long-term commercial roadmap targets scaling to 1,000 physical qubits, progressing toward 1,000 logical, fault-tolerant qubits on chip by 2030 housed within a deployable data-center form factor.

Unlike monolithic quantum architectures that force qubits into tight physical proximity, which creates severe crosstalk, control complexity and thermal bottlenecks, NVision’s Photonic Integrated Quantum Circuit (PIQC) architecture uses optical links to decouple qubits from local spatial constraints. The engineered carbene molecules function at accessible cryogenic temperatures (2K – 4K) and emit photons natively at precise optical frequencies, enabling direct intra-chip and inter-chip quantum entanglement.

“Chemistry gives us a design freedom that semiconductor-based qubits, such as in silicon, simply do not have. By addressing quantum design at the molecular level, we can tune the performance that matters most, including quantum memory, gate speed and photon emission, within a single molecule,” said Dr. Ilai Schwartz, CTO of NVision. “Because our qubits interact directly with light from the start, we achieve connectivity without proximity, making photonic networking a foundational capability of our platform rather than something we have to add later.”

To achieve this milestone, NVision combined large-scale computational screening with targeted synthesis, evaluating more than 150 candidate molecules, out of which 40 were synthesized in the laboratory. The resulting carbene system is engineered to interface directly with photons, making photonic connectivity a practical building block for scalable architectures. Crucially, the platform tolerates up to 70% photon loss, enabling reliable operation with standard silicon photonics rather than requiring ultra-low-loss, specialized optical infrastructure.

First prototype integrated chips resulting from the collaboration are expected in Q4 2026. For detailed technical specifications, architectural white papers, and access to the peer-reviewed Nature study (DOI: 10.1038/s41586-026-11147-6), read  Designed, not Discovered: A Molecule Built to Be a Qubit.

Prineha Narang, Partner, DCVC:

“At DCVC, we’re excited to back NVision because we believe its molecular qubit platform has the potential to accelerate the roadmap for quantum computing as a whole. Using molecules as the building blocks of quantum hardware is a visionary approach, one that could make qubits easier to manufacture, scale, and industrialize. This is the kind of innovation that could bring us closer to realizing quantum computing’s promise, including the discovery of new materials and molecules.”

Peter Barrett, Co-Founder and General Partner, Playground Global:

“The ability to read and write spin states with light is a breakthrough in our ability to control the quantum nature of nature. NVision brings manufacturability and the design freedom of chemistry to quantum computing, with molecular qubits that could be integrated directly onto photonic chips. It opens a remarkable possibility: designing molecules to build computers that can, in turn, help us design entirely new forms of matter.” 

Avi Eyal, Managing Partner, Entrée Capital:

“From the start, the NVision team chose to solve quantum’s scaling problem at the molecular level rather than brute-force it with ever-larger fabrication plants. The announcement today puts NVision among the few companies with a credible, manufacturable path to quantum computing at scale. Few teams anywhere combine this depth in quantum physics, organic chemistry and photonics, and we’re proud to support them as they move from foundational science to commercial hardware.”

Christian Reitberger, Founding Partner, Matterwave Ventures:

“It is exciting to see NVision’s quantum metabolic imaging work being complemented by a computing modality that will benefit rational drug design, thus enabling a fast design to metabolic testing loop. That the carbene-photon interface can be realized on existing commercial PIC technology is crucial for a capital efficient path towards a useful computing system.”

Marco Allegretti, Senior Partner of AI Fund at CDP Venture Capital:

“This important milestone reflects both the strength of NVision’s vision and the outstanding execution demonstrated by its team. The publication in Nature and the partnership with HyperLight mark a significant validation of the company’s technological journey and further strengthen the investment thesis that convinced us to support NVision from its earliest stages.”

Dr. Itamar Sivan, Co-Founder and CEO, Quantum Machines:

“NVision’s achievement introduces an exciting new building block for quantum computing, bringing together molecular qubits and photonic connectivity with a vision for scale. Quantum Machines’ control platform brings these elements together, helping turn pioneering science into working quantum systems. We’re delighted to contribute to this milestone and to work alongside NVision as they build toward scalable quantum computers.”
 

About NVision Quantum Technologies 

NVision is a full stack quantum technology company focused on healthcare, with deep expertise in engineering and controlling the quantum properties of organic molecules. This approach underpins both its POLARIS platform, which enables real-time measurement of metabolism on standard MRI systems, and its quantum computing platform, Photonic Integrated Quantum Circuits (PIQC, pronounced “Pixie”). Together, these capabilities are helping bridge the gap between understanding disease and delivering effective therapies. Founded in 2015 and headquartered in Ulm, Germany, NVision is backed by Playground Global, DCVC, Entrée Capital, Matterwave/b2venture, Lauder Partners, Pathena Investments, The European Investment Bank and others. Learn more at nvision-quantum.com.

About HyperLight

HyperLight delivers high-performance integrated photonics solutions based on thin-film lithium niobate technology. The company combines the electro-optic advantages of TFLN with scalable manufacturing, test, and integration to enable next-generation optical engines for AI data centers, telecom and metro networks, and emerging photonics markets.

 

Media Contact:

For high-resolution images or any other inquiries, please contact press@nvision-quantum.com


28.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


2424016  28.10.2026 CET/CEST

Eckert & Ziegler Receives GMP Certificate for Actinium-225

Eckert & Ziegler SE

/ Key word(s): Regulatory Approval

Eckert & Ziegler Receives GMP Certificate for Actinium-225

28.10.2026 / 14:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


Braunschweig, Germany, 28 October 2026. Eckert & Ziegler Therapeutics GmbH, wholly owned subsidiary of Eckert & Ziegler SE (ISIN DE0005659700, TecDAX), has received the manufacturing authorization for Actinium-225 (Ac-225). The certification by the competent German authority confirms that production meets the stringent requirements of Good Manufacturing Practice (GMP) and facilitates the use of the radioisotope for the investigational treatment of patients.

Actinium-225 is widely regarded as one of the most promising alpha emitters for use in targeted radiopharmaceutical applications. This is reflected in both the increasing number of clinical trials investigating this radionuclide and the advancement of clinical programs into later-stage development.

“This regulatory milestone is the decisive step that turns our production capability into a supply commitment the field can build their clinical and commercial programs on,” said Dr. Gunnar Mann, Member of the Executive Board and responsible for Operations at Eckert & Ziegler’s Medical Segment. “We have quickly moved from first production runs in our upscaled process to GMP grade routine manufacturing. This is what improving supply security looks like in practice.”

The overall production route uses cyclotron-based irradiation of Radium-226 (Ra-226) at the Řež facilities of the Czech Academy of Sciences’ Nuclear Physics Institute (Ústav jaderné fyziky, “UJF”). Afterwards the irradiated material is processed at Eckert & Ziegler’s Braunschweig site to obtain GMP grade Ac-225. Production activities at both sites are supported by custom-engineered hot cell systems from Isotope Technologies Dresden GmbH, Eckert & Ziegler’s hot cell division.

The proprietary process set up by Eckert & Ziegler ensures that the cyclotron-based production of Ac-225 results in an isotopic profile with long-lived impurities such as Actinium-227 and Thorium-229 kept to a minimum, thereby meeting the expectations of nuclear medicine physicians and radiopharmacists alike.

Secured access to Radium-226
Accessing Ra-226 as the precursor material is one of the principal bottlenecks in global Ac-225 production. To alleviate the pressure on its supply chain, Eckert & Ziegler has integrated the repurposing of Ra-226 legacy sources into its sourcing strategy. Additionally, the production method recovers unconverted Ra-226 after irradiation and reintroduces it to the process, allowing the material to be used across multiple cycles. This helps reduce dependency on constrained global Ra-226 inventories while limiting radioactive waste, contributing to more predictable output volumes and costs for both radioisotope supply and CDMO programs.

Capacity expansion in Asia and North America
The newly opened production facility of Eckert & Ziegler’s joint venture Qi Kang Medical Technology (Changzhou) Co., Ltd. in Jintan, China is intended to become the first site in the country dedicated to the production of Ac-225 on a commercial scale. This second phase is planned to be realized after initial operations start in early 2027.
In addition, further capacity expansion can be considered at Eckert & Ziegler’s established radiopharmaceutical manufacturing site near Boston, MA, USA, as well as in Germany, to support the future commercial supply of Ac-225-based medicinal products.

About Eckert & Ziegler
Eckert & Ziegler SE, with more than 1,100 employees, is THE leading independent radioisotope supplier and a specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Contact
Eckert & Ziegler SE
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations
jan.schoepflin@ezag.de / karolin.riehle@ezag.de
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com


28.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Eckert & Ziegler SE
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-0
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX, TecDax,
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate BSX
LEI Code: 391200EUDABLUKXCKG48
EQS News ID: 2416898

 
End of News EQS News Service

2416898  28.10.2026 CET/CEST

DEBRA Research Invests in Topadur to Advance Small-Molecule Therapies for Dystrophic Epidermolysis Bullosa

Topadur Pharma AG

/ Key word(s): Financing

DEBRA Research Invests in Topadur to Advance Small-Molecule Therapies for Dystrophic Epidermolysis Bullosa

28.10.2026 / 11:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


DEBRA Research Invests in Topadur to Advance Small-Molecule Therapies for Dystrophic Epidermolysis Bullosa

Preclinical program will evaluate Topadur’s proprietary, locally acting compounds, including clinical-stage TOP-N53, which target key disease processes in dystrophic Epidermolysis bullosa, a rare and debilitating genetic skin disorder

Munich, Germany, and Schlieren-Zurich, Switzerland, 28 October 2026 – DEBRA Research gGmbH, a global non-profit organization dedicated to advancing research and drug development for Epidermolysis bullosa (EB), and Topadur Pharma AG, a Swiss clinical-stage biopharmaceutical company, today announced an investment by DEBRA Research in Topadur to support a preclinical program exploring a new treatment approach for dystrophic Epidermolysis bullosa (DEB). DEB is one of the more severe forms of EB, characterized by extremely fragile skin and progressive, debilitating complications.

The program will evaluate Topadur’s clinical-stage compound TOP-N53 together with additional selected small molecules from its proprietary DualTOP® platform. The compounds will be investigated in in vitro and in vivo models addressing two major and interconnected challenges in DEB: impaired wound healing and fibrosis. The studies will be conducted in collaboration with the Medical Center – University of Freiburg, Germany, and EB Research Institute GmbH in Salzburg, Austria.

“People living with dystrophic EB face severe complications that extend far beyond chronic wounds,” said Prof. Hubert Trübel, MD, MBA, Managing Director of ReadOn Therapeutics, a DEBRA Research spinout. “Through our investment in Topadur, we are supporting the development of locally acting therapies that target several interconnected aspects of the disease. We see this as an important step toward exploring new approaches that go beyond wound management alone.”

“DEBRA Research brings deep expertise in EB and a strong understanding of the needs of people living with this devastating disease. Their support as an investor and partner in this program is an important endorsement of our approach and underscores the broader potential of our DualTOP® platform in indications with significant unmet medical needs,” said PD Dr. Matthias Schäfer, CEO of Topadur Pharma AG.

EB comprises a group of rare genetic conditions characterized by extremely fragile skin that is prone to blistering and wounds, even from minor friction or trauma. In DEB, mutations in the COL7A1 gene impair collagen VII, resulting in recurrent skin lesions within the dermis. Repeated cycles of injury and repair can lead to chronic wounds, progressive fibrosis, scarring, and severe functional impairment. Despite recent advances in wound treatment, there is still a significant need for therapies addressing these interconnected disease processes.

Topadur’s DualTOP® platform comprises locally acting small molecules designed to modulate complementary signalling pathways involved in tissue repair and disease progression. TOP-N53, Topadur’s lead asset, has demonstrated wound-healing activity in preclinical models and increased local skin perfusion in a first-in-human Phase 1 study, where it was well tolerated. It is currently in Phase 2a clinical development for digital ulcers in systemic sclerosis and has received Orphan Drug Designation from both the FDA and EMA. Across the broader DualTOP® platform, Topadur compounds have also demonstrated anti-fibrotic activity in preclinical models. The DEB program will investigate these complementary properties in disease-relevant models.

About Topadur Pharma AG

Topadur Pharma AG, based in Schlieren-Zurich, Switzerland, is a clinical-stage biopharmaceutical company developing locally acting small-molecule therapies. Its proprietary DualTOP® platform targets the cGMP signalling pathway, a central regulator of vascular regeneration and tissue repair. Building on this technology, the company is advancing a pipeline of therapeutic candidates for age- and disease-related conditions with significant unmet medical needs. Topadur’s lead candidate, TOP-N53, is undergoing Phase 2a clinical evaluation for the treatment of digital ulcers in patients with systemic sclerosis. In parallel, TOP-M119 is being prepared for first-in-human clinical trials targeting alopecia.

For more information, please visit www.topadur.com and follow Topadur on LinkedIn.

About DEBRA Research

DEBRA Research is a non-profit organization dedicated to advancing treatments and cures for Epidermolysis Bullosa (EB), a rare and life-limiting genetic condition. As the research arm of DEBRA Austria – a patient organization established in 1995 to support individuals living with EB – DEBRA Research collaborates globally with academia, biotech, pharma, patient organizations, and regulatory bodies to drive innovation. DEBRA Research focuses on translational research and clinical development to address the unmet needs of people living with EB. Its goal is to accelerate the discovery and development of treatments improving their quality of life, while striving for a future where EB is curable – a “world without EB.”

For more information, please visit www.debra-research.org and follow us on LinkedIn.

Contacts

DEBRA Research
Prof. Hubert Trübel
info@debra-research.org

Topadur Pharma AG
Yoshita Bhide
Media Communications
+41 44 755 44 66
yoshita.bhide@topadur.com

Media inquiries

MC Services
Anne Hennecke, Dr. Johanna Kobler, Julia Bittner
+49 89 210 2280
contact@mc-services.eu
 

Disclaimer (Topadur Pharma AG)

TOP-N53 and the other compounds referred to in this press release are investigational and have not been approved by any regulatory authority. The program in dystrophic epidermolysis bullosa is at the preclinical stage; the safety and efficacy of these compounds in epidermolysis bullosa have not been established.

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Topadur Pharma AG (Topadur). This publication may contain certain forward-looking statements and assessments or intentions concerning Topadur and its business, including the research program described in this release. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Topadur to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. Topadur disclaims any obligation to update these forward-looking statements, assessments or intentions.


28.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


2423720  28.10.2026 CET/CEST

Straumann Group accelerates organic growth to 9.2% and confirms full-year 2026 outlook

  • Third-quarter revenue amounted to CHF 667.1 million, with organic growth accelerating to 9.2%; revenue for the first nine months reached CHF 2.0 billion, up 8.3% organically
  • iEXCEL continued to gain market share in premium implantology
  • Launch of new Straumann F.A.S.T. digitally powered implant treatment solutions, including SIRIOS APS for full-arch scanning, supporting clinical efficiency and practice profitability
  • Growing adoption of Straumann AXS deepens customer engagement and supports recurring sales of implants and treatment consumables
  • Full-year 2026 outlook confirmed: high single-digit organic revenue growth and core EBIT margin expansion of around 140 to 170 basis points at constant 2025 exchange rates

 

revenue by region

Figures refer to continuing operations, 

in CHF million

 

Q3 2026

Q3 2025

9M 2026

9M 2025

Europe, Middle East & Africa (EMEA)

256.0

234.0

829.5

784.4

 Change CHF

9.4%

8.2%

5.8%

6.6%

 Change (CER[1])

10.5%

11.2%

8.9%

9.7%

 Change organic

10.5%

11.2%

8.9%

9.7%

 % of Group total

38.4

38.9

40.5

40.2

 

 

 

 

 

North America (NAM)

174.9

161.6

527.3

517.4

 Change CHF

8.2%

(0.8%)

1.9%

(0.9%)

 Change (CER1)

7.5%

5.7%

7.9%

3.3%

 Change organic

7.5%

5.7%

7.9%

3.3%

 % of Group total

26.2

26.8

25.8

26.5

 

 

 

 

 

Asia Pacific (APAC)

165.6

144.3

490.4

475.8

 Change CHF

14.8%

(3.4%)

3.1%

9.4%

 Change (CER1)

10.3%

3.2%

6.1%

14.1%

 Change organic

10.3%

3.2%

6.1%

14.1%

 % of Group total

24.8

24.0

24.0

24.4

 

 

 

 

 

Latin America (LATAM)

70.5

62.3

199.4

172.8

 Change CHF

13.1%

9.8%

15.4%

4.2%

 Change (CER1)

6.5%

18.0%

12.1%

17.7%

 Change organic

6.5%

18.0%

12.1%

17.7%

 % of Group total

10.6

10.3

9.7

8.9

 

 

 

 

 

Group

667.1

602.2

2 046.5

1 950.4

 Change CHF

10.8%

2.9%

4.9%

4.9%

 Change (CER1)

9.2%

8.3%

8.3%

9.6%

 Change organic

9.2%

8.3%

8.3%

9.6%

 

Basel, October 28, 2026: Straumann Group reported third-quarter revenue of CHF 667.1 million, representing 9.2% organic growth and a 10.8% increase in Swiss francs compared with the prior-year period. Revenue for the first nine months reached CHF 2.0 billion, up 8.3% organically. Following the strong second-quarter performance, organic growth accelerated further, with all regions contributing. Europe, Middle East and Africa (EMEA) and Asia Pacific (APAC) delivered double-digit growth. North America (NAM) delivered very solid growth in a soft demand market. In Latin America (LATAM), growth was driven primarily by the Hispanic markets outside Brazil, where lower implant penetration provides further opportunities for expansion. Premium implants, the Group’s challenger implantology brands and digital solutions supported the performance. In orthodontics, the transformation is progressing as planned, with new ClearCorrect solutions and digital launches improving treatment efficiency and strengthening the brand’s value proposition.

 

Guillaume Daniellot, Chief Executive Officer, commented: “I am proud of our teams for delivering another strong quarter. Continued share gains for iEXCEL reinforce our leadership in premium implantology, while Neodent keeps on expanding access to treatment in more markets.

Our intraoral scanners have accounted for one of the largest shares of units sold worldwide so far this year. Powered by the new SIRIOS APS unique full-arch scanning technology, the new Straumann F.A.S.T. Full Arch workflow significantly improves the efficiency of advanced full arch treatments. Straumann AXS brings this seamless end to end solution together and further supports practice profitability, avoiding significant investment in additional expensive devices. With those innovations, we remain confident in delivering our full-year outlook.

Finally, after almost 20 years with Straumann Group, I feel honored and humbled to have contributed to its transformation and success, through having always focused on constantly creating value for our customers worldwide. I thank our colleagues, customers and partners for their trust and look forward to the Group’s next chapter under Christopher’s leadership.”

 

REGIONAL PERFORMANCE IN THE THIRD QUARTER

EMEA – Double-digit growth led by premium and challenger implantology

EMEA generated revenue of CHF 256.0 million with +10.5% organic growth. Premium implantology strengthened during the quarter, with iEXCEL continuing to attract new customers and drive conversions. Neodent and Anthogyr supported growth in the Group’s challenger implant segment. The “DACH” region, comprising Germany, Austria and Switzerland, made important contributions, alongside strong momentum in Poland, Romania and Hungary. Educational events, including the International Esthetic Days (iED) and the European Association for Osseointegration (EAO) Congress, strengthened customer engagement and introduced new treatment solutions. ClearCorrect continued to expand in selected European markets, supported by a more focused allocation of resources.

 

NAM – Growth supported by implantology and digital solutions

North America generated revenue of CHF 174.9 million with +7.5% organic growth, delivering very solid growth despite cautious consumer sentiment and broadly stable patient flow. Premium implantology and Neodent progressed well supported by a dynamic pace of customer conversions.

Continued demand for intraoral scanners also contributed to the good performance. ClearCorrect grew in the competitive clear-aligner market, supported by digital tools to assess cases and monitor treatment remotely.

 

APAC – Double-digit growth and strong performance outside China

Asia Pacific generated revenue of CHF 165.6 million, with organic growth accelerating to 10.3%. APAC excluding China performed well in the third quarter with strong growth in Japan and India, supported by iEXCEL and commercial activities around our challenger brands across Southeast Asia. China returned to growth after several challenging quarters marked by uncertainty surrounding volume-based procurement (VBP), contributing to the region’s stronger performance. Rules for the next round of VBP for dental implants have not yet been announced, and implementation is currently anticipated in the first quarter of 2027. The Group’s portfolio of brands across price segments and its local manufacturing capabilities position it well to address the market’s evolving needs.

 

LATAM – Neodent drives further growth by expanding to Hispanic markets

Latin America generated revenue of CHF 70.5 million with +6.5% organic growth, a moderation from the first half of the year. In Brazil, the region’s largest and more mature implant market, patient flow through large dental groups lost momentum and purchasing slowed. Scanner sales also normalized after rapid adoption last year. These developments weighed on regional growth, while Neodent continued to expand in Hispanic markets, particularly Mexico and Colombia, where implant penetration is lower. Premium implantology advanced, and the Group is expanding its coverage of private practices in Brazil to reach more clinicians. In September, the Group opened its third Neodent factory in Curitiba, adding capacity for the brand’s global expansion.

 

STRATEGIC Update

Full arch – Digitally powered treatment from scan to new teeth

Full-arch restorations, which replace all teeth in one jaw with a fixed solution supported by multiple implants, represent a substantial growth opportunity across the Group’s markets. Straumann’s intraoral scanners have been among the global leaders in units sold so far this year, giving the Group a strong base to reach more practices. The new SIRIOS APS (Arch Positioning System) uses unique small reference components on iEXCEL implants to capture their positions digitally, offering a cost-effective alternative to conventional impressions or dedicated and expensive scanning equipment for full-arch treatments. It forms part of Straumann F.A.S.T. (Fast, Accurate, Simple, Trusted), a family of new digitally powered treatment workflows connecting scanning, planning, implant placement and restoration. The new full-arch workflow allows clinicians and dental laboratories to work on the same digital case, aiming to reduce treatment time, improve practice efficiency and get patients to new teeth sooner.

 

Straumann AXS – Growing adoption creates lasting customer value

Strong growth in intraoral scanner sales, particularly SIRIOS, is bringing more clinicians into Straumann’s digital ecosystem. Straumann AXS, the Group’s open cloud-based platform, connects scanning, treatment planning and product ordering and now has more than 20 000 active users. Initial customer analysis is indicating that revenue from an AXS user is growing faster than the non-user group, as reorder rates for AXS customers are substantially higher than for non-AXS customers.

By bringing these steps into clinicians’ daily workflows and making repeat ordering easier, AXS supports lasting customer relationships and recurring sales of implants and treatment consumables.

 

ClearCorrect – A sharper offering for priority markets

ClearCorrect achieved double-digit growth in its priority markets as the orthodontics transformation progressed. Focusing commercial resources on these markets and improving production and operations have reduced costs. In October, ClearCorrect began rolling out a broader wave of innovations for general practitioners, including outcome simulation linked to SIRIOS scanning and additional aligner trimline options in selected markets. Together with Case Assessment, which helps clinicians select suitable cases, and RemoteCare, which supports follow-up between visits, these tools make aligner treatment easier to integrate into general dental practices. The stronger offering and more efficient cost base reinforce ClearCorrect’s position in its target segment and keep the business on track to reach break-even by the end of 2027.

 

Renata Putnik to assume the Chief People Officer role on January 1, 2027

Arnoud Middel has decided to leave Straumann Group at the end of 2026. We thank him for his dedicated leadership and lasting contribution to our global People & Culture organization and talent development, as well as for supporting Renata Putnik’s development which has helped secure a strong internal succession, reflecting the depth of talent at Straumann Group and ensuring continuity in People & Culture leadership as we enter 2027.

Renata Putnik will succeed him as Chief People Officer on January 1, 2027. In more than ten years at Straumann Group, she has held global and regional HR roles and most recently led HR in North America. The Group welcomes her appointment, recognizing her business acumen, strategic perspective and collaborative leadership, alongside her deep understanding of the company and its culture.

 

OUTLOOK FOR THE FULL-YEAR 2026 – BARRING UNFORESEEN EVENTS

Straumann Group continues to expect high single-digit organic revenue growth for the full-year 2026 and confirms its profitability guidance, raised in June, for core EBIT margin expansion of around 140 to 170 basis points at constant 2025 exchange rates. The improvement is expected to be evenly distributed between the first and second half of the year.

The Group remains confident in its ability to deliver on its outlook, supported by the significant growth opportunities in its global CHF 20 billion addressable market, its resilient business model with strong market positions in a continued volatile environment, its innovation and transformation initiatives, and its highly engaged, entrepreneurial culture driving disciplined execution. Its broad global footprint provides a solid foundation for capturing significant growth opportunities in the global oral care market.

 

About Straumann Group

The Straumann Group (SIX: STMN) is a global leader in tooth replacement and orthodontic solutions that restore smiles and confidence. It unites global and international brands that stand for excellence, innovation and quality in replacement, corrective and digital dentistry, including Anthogyr, ClearCorrect, Medentika, Neodent, NUVO, Straumann and other fully/partly owned companies and partners. In collaboration with leading clinics, institutes and universities, the Group researches, develops, manufactures and supplies dental implants, instruments, CADCAM prosthetics, orthodontic aligners, biomaterials and digital solutions for use in tooth correction, replacement and restoration or to prevent tooth loss.

 

Headquartered in Basel, Switzerland, the Group currently employs around 12 000 people worldwide. Its products, solutions and services are available in more than 100 countries through a broad network of distribution subsidiaries and partners.

***

Straumann Holding AG, Peter Merian-Weg 12, 4002 Basel, Switzerland

Phone: + 41 (0)61 965 11 11

Homepage: www.straumann-group.com

 

Contacts

Corporate Communications

Investor Relations

Silvia Dobry:

+41 (0)61 965 15 62

Marcel Kellerhals:

+41 (0)61 965 17 51

Marc Kaiser:

+41 (0)61 965 16 80

Derya Güzel:

+41 (0)61 965 18 76

E-mail: corporate.communication@straumann.com

E-mail: investor.relations@straumann.com

 

analysts’ and media conference call

Straumann Group will present its 2026 third-quarter results to representatives of the financial community and media in a webcast conference call today at 10.30 a.m. CET. The webcast can be accessed via www.straumann-group.com/webcast. A replay of the webcast will be available after the conference.

 

If you intend to ask a question during the Q&A session, we kindly ask you to pre-register for the conference call through this link. We also recommend that you download the presentation file in advance using the conference call.

 

Presentation

The conference presentation slides are attached to this release and available on the Media and Investors pages at www.straumann-group.com.

 

 

upcoming corporate / Investor events

2026

Event

Location

October 29, 2026

Roadshow Bank of America

Paris

November 4, 2026

Roadshow J.P. Morgan

London

November 5, 2026

ZKB Swiss Equity Conference

Zurich

November 10-11, 2026

UBS European Conference

London

November 24, 2026

Kepler Cheuvreux Geneva Day

Geneva

December 7-8, 2026

Roadshow Kepler Cheuvreux

Brussels, Amsterdam

December 8-9, 2026

Roadshow Barclays

New York, Boston

December 14-15, 2026

Roadshow ODDO BHF

Paris

Dec 31, 2026 – Feb 23, 2027

Quiet period

 

February 24, 2027

Full-year 2026 results

Basel

 

Disclaimer

This press release contains forward-looking statements that reflect the current views, beliefs and expectations of management at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, pandemics, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Straumann’s control. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Straumann is providing the information in this release as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events, or otherwise. This release constitutes neither an offer to sell nor a solicitation to buy any securities.

 

###


[1] Constant exchange rate (CER) equals prior-year figures at 2025 currency exchange rates

BIO-Europe 2026 to Convene Global Biopharma Leaders in Cologne as Dealmaking Confidence Grows

Informa Connect

/ Key word(s): Conference

BIO-Europe 2026 to Convene Global Biopharma Leaders in Cologne as Dealmaking Confidence Grows

27.10.2026 / 15:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


BIO-Europe 2026 to Convene Global Biopharma Leaders in Cologne as Dealmaking Confidence Grows

London, UK – October 27, 2026 – BIO-Europe 2026 will bring together more than 6,000 senior executives from the global biotech, pharmaceutical, and investment sectors in Cologne, Germany, November 9–11, 2026. Now in its 32nd edition, the event comes at a time of renewed confidence in biopharma dealmaking, despite continued financing challenges.

“While 75% of senior biopharma leaders expect appetite for partnering and M&A to increase over the next 12 months. The industry continues to face fundamental questions about how scientific innovation is financed, developed, and brought to patients,” said Claire Macht, Senior Portfolio Director, Europe, Informa Connect. “BIO-Europe provides a neutral platform for senior leaders to challenge established approaches, exchange perspectives, and address the strategic decisions shaping the future of biopharma.”

The findings, from the inaugural Biopharma C-Suite Agenda Survey 2026 (81 senior executives, including 50 CEOs), will anchor BIO-Europe’s Big Picture Plenary Series.

Rethinking Europe’s Biotech Business Models and Financing

As European biotech companies navigate changing capital markets and regulatory environments, industry leaders are increasingly questioning whether established business models can support the next generation of breakthrough therapies.

“CEOs need to speak up: when governments make drug development harder, patients pay the price. Titans must take responsibility,” said Jeremy Levin, Prior CEO Teva Pharmaceuticals. “Big venture funds must back young, science-based companies, or Europe will keep exporting the science and buying back the medicines. Now is the time to invest in innovation.”

“There is now a critical pre-clinical funding gap in Europe as bigger VC funds focus on later-stage clinical development,” said Edwin Moses, Chairman of NanoSyrinx, LabGenius, and Avantium. “These big funds should consider creating new agile vehicles with specialist managers and risk appetite to ensure there is a biotech product pipeline for the future. Innovation in speeding up regulatory pathways is a major opportunity for Europe to lead the way – let’s take the lead and simplify.”

Levin and Moses will debate these issues further at the Big Picture plenary, “Building a Biotech in a Changing World – Europe’s Choices,” examining whether traditional biotech business models can sustain breakthrough innovation amid shifting capital markets, platform-based company creation, and advances in AI.

These challenges will be explored further in a second Big Picture plenary, “Building a Competitive and Impactful European Biotech Community: Perspectives from the European Life Sciences Coalition and CEOs.” The session will introduce the newly established European Life Sciences Coalition (ELSC) and invite participants to support an open letter to European leaders. Moderated by Melanie Senior, the discussion will feature representatives from Andera Partners, Angelini Ventures, Tubulis, and argenx, examining how institutional capital, regulatory pathways, and deeper public capital markets can support biotech company creation and growth in Europe.

Building Globally Competitive Biotech Ecosystems

Beyond financing and regulatory reform, the conference will examine how innovation ecosystems can help biotech companies grow and compete internationally. The session “Building the Next Global Biotech Hubs: What Makes an Innovation Ecosystem Work?” will explore how talent, research infrastructure, investment, and industry collaboration combine to build successful life sciences clusters.

As host region, North Rhine-Westphalia provides an example of an established life sciences ecosystem, bringing together industry, research institutions, and healthcare organizations.

“North Rhine-Westphalia combines scientific excellence with a strong and diverse life sciences industry. Hosting BIO-Europe in Cologne puts our regional capabilities on an international stage,” said Dr. Stefan Rensch of Bio.NRW. “For our companies and research institutions, the event offers direct access to potential investors, pharmaceutical partners, and international markets, helping turn the region’s research and innovation strengths into commercial opportunities.”

Partnering and Registration for BIO-Europe 2026

One-to-one partnering is now open through partneringONE®.

A Digital Partnering Pass offers virtual partnering days on November 17–18, 2026, plus on-demand content, including company presentations and panel discussions.

Registration is open via the the BIO-Europe website, with discounted rates available through November 6, 2026.

About Informa Connect

Informa Connect, a division of Informa PLC, creates global platforms where industries connect, learn, and collaborate through events, digital services, and professional communities. Through its life sciences portfolio, Informa Connect brings together senior executives, investors, and strategic partners to exchange insights, build relationships, and drive innovation across global markets.

For more information, please visit: https://informaconnect.com/bioeurope/

Follow BIO-Europe 2026 on LinkedIn or X @EBDGroup (hashtag: #BIOEurope2026)

Media Contacts:
Informa Connect contacts

Ryan Hui
lifesciencepress@informa.com

MC Services AG contacts

Brittney Sojeva
Senior Consultant
brittney.sojeva@mc-services.eu
+49 211 529 252 14


27.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


2423008  27.10.2026 CET/CEST

Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer

Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer




Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer

  • Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1
  • First EU approval of Enhertu in the curative-intent early breast cancer setting
  • Third approval for Enhertu in the EU in four months

TOKYO–(BUSINESS WIRE)–Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment.


Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN).

The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine.

In DESTINY-Breast05, Enhertu significantly reduced the risk of invasive disease recurrence or death (invasive disease-free survival [IDFS]) by 53% (hazard ratio [HR]=0.47; 95% confidence interval [CI]: 0.34-0.66; p<0.0001) compared to trastuzumab emtansine (T-DM1) in patients with HER2 positive breast cancer with residual invasive disease following neoadjuvant therapy. Enhertu demonstrated a three-year IDFS rate of 92.4% (95% CI: 89.7-94.4) and 83.7% with T-DM1 (95% CI: 80.2-86.7). Data also showed that Enhertu significantly reduced the risk of disease recurrence or death (disease-free survival [DFS]) by 53% (HR=0.47; 95% CI: 0.34-0.66; p<0.0001) compared to T-DM1. Results showed a three-year DFS rate of 92.3% (95% CI: 89.5-94.3) in the Enhertu arm and 83.5% with T-DM1 (95% CI: 79.9-86.4).

“For patients with HER2 positive early breast cancer and residual invasive disease after neoadjuvant therapy, reducing the risk of disease recurrence is critical for sustained long-term outcomes,” said Sibylle Loibl, MD, PhD, GBG (German Breast Group) and Goethe University Medicine Frankfurt, Frankfurt am Main and lead investigator of the DESTINY-Breast05 trial. “The EU approval of trastuzumab deruxtecan, which demonstrated a more than 50% reduction in risk of recurrence compared to standard of care in DESTINY-Breast05, has the potential to change how we treat eligible patients in this setting.”

In DESTINY-Breast05, the safety profile of Enhertu was consistent with the known profile with no new safety concerns identified. Grade 3 or grade 4 adverse reactions from a pooled safety analysis of 4,146 patients who received at least one dose of Enhertu (5.4 mg/kg) in clinical studies across multiple tumor types included neutropenia (18.7%), anemia (8.2%), fatigue (7.4%), leukopenia (6.6%), thrombocytopenia (5.4%), lymphopenia (5.0%), nausea (4.5%), increased transaminases (3.3%), hypokalemia (3.1%), pancytopenia (2.8%), diarrhea (2.1%), vomiting (2.0%), decreased appetite (1.4%) and pneumonia (1.2%). Grade 5 adverse reactions occurred in 0.9% of patients, including interstitial lung disease (ILD)/pneumonitis (0.8%).

“By bringing Enhertu into the adjuvant setting, we are advancing this treatment option earlier in the course of disease for patients with HER2 positive early breast cancer,” said Ken Keller, Global Head of Oncology Business, and President and CEO, Daiichi Sankyo, Inc. “This first approval of Enhertu in early breast cancer in the EU reflects our continued commitment to bringing innovative medicines into earlier treatment settings, where there is significant potential to improve long-term outcomes for patients.”

“The goal of treatment in early breast cancer is to help as many patients as possible achieve cure. Unfortunately, despite treatment advances, some patients still face recurrence in the long-term,” said Dave Fredrickson, Executive Vice President, Oncology Hematology Business Unit, AstraZeneca. “The approval of Enhertu in the adjuvant setting for patients with residual disease after neoadjuvant treatment has the potential to establish a new benchmark in this curative-intent setting, with more than 92% of patients alive and free of invasive disease at three years.”

Enhertu (5.4 mg/kg) is now approved in more than 35 countries/regions worldwide for the adjuvant treatment of adult patients with HER2 positive breast cancer who have residual invasive disease following neoadjuvant trastuzumab (with or without pertuzumab) and taxane-based treatment based on the DESTINY-Breast05 trial.

Financial Considerations

Following this approval in the EU, an amount of $75 million is due from AstraZeneca to Daiichi Sankyo as a milestone payment for the adjuvant HER2 positive early breast cancer indication. Sales of Enhertu in most EU territories are recognized by Daiichi Sankyo. For further details on the financial arrangements, please consult the collaboration agreement from March 2019.

About DESTINY-Breast05

DESTINY-Breast05 is a global, multicenter, randomized, open-label, phase 3 trial evaluating the efficacy and safety of Enhertu (5.4 mg/kg) versus T-DM1 in patients with HER2 positive early breast cancer with residual invasive disease in breast or axillary lymph nodes following neoadjuvant therapy and a high risk of recurrence. High risk of recurrence was defined as presentation with inoperable cancer (prior to neoadjuvant therapy) or pathologically positive axillary lymph nodes following neoadjuvant therapy.

The primary endpoint of DESTINY-Breast05 is investigator-assessed IDFS, which is defined as the time from randomization until first invasive local, axillary or distant recurrence or death from any cause. The key secondary endpoint is investigator-assessed DFS. Other secondary endpoints include overall survival, distant recurrence-free interval, brain metastases-free interval and safety.

DESTINY-Breast05 enrolled 1,635 patients in Asia, Europe, North America, Oceania and South America. For more information about the trial, visit ClinicalTrials.gov.

About HER2 Positive Early Breast Cancer

Breast cancer is the most common cancer in women worldwide and the leading cause of cancer-related deaths among women.1 Approximately 2.4 million breast cancer cases were diagnosed in 2024, with more than 690,000 deaths globally.1 In Europe, approximately 540,000 cases of breast cancer were diagnosed in 2024, with more than 140,000 deaths.2

HER2 is a tyrosine kinase receptor growth-promoting protein expressed on the surface of many types of tumors including breast cancer.3 HER2 protein overexpression may occur as a result of HER2 gene amplification and is often associated with aggressive disease and poor prognosis in breast cancer.3 Approximately one in five cases of breast cancer is considered HER2 positive.4

Approximately one in three patients with HER2 positive early-stage breast cancer is considered high-risk, meaning they are more likely to experience disease recurrence and have a poor prognosis.5 Despite receiving additional treatment with current standard of care for residual disease, some patients still experience invasive disease or death.6 Once patients are diagnosed with metastatic disease, the five-year survival rate drops from nearly 100% to approximately 34%.7

Adjuvant therapy represents a key opportunity to minimize the risk of recurrence and prevent progression to metastatic disease for patients with residual disease.8,9,10 Prior to the approval of Enhertu in the HER2 positive adjuvant (after surgery) setting for patients with residual invasive disease, the standard of care was T-DM1.11

About Enhertu

Enhertu (trastuzumab deruxtecan; fam-trastuzumab deruxtecan-nxki in the U.S. only) is a HER2 directed ADC. Designed using the proprietary DXd ADC Technology of Daiichi Sankyo, Enhertu is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced program in AstraZeneca’s ADC scientific platform. Enhertu consists of a HER2 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers.

Enhertu (5.4 mg/kg) followed by THP is approved in more than five countries/regions worldwide as a neoadjuvant treatment for adult patients with HER2 positive (IHC 3+ or ISH+) stage 2 or stage 3 breast cancer based on the results from the DESTINY-Breast11 trial.

Enhertu (5.4 mg/kg) is approved in more than 35 countries/regions worldwide for the adjuvant treatment of adult patients with HER2 positive breast cancer who have residual invasive disease following neoadjuvant trastuzumab (with or without pertuzumab) and taxane-based treatment based on the DESTINY-Breast05 trial.

Enhertu (5.4 mg/kg) in combination with pertuzumab is approved in more than 40 countries/regions worldwide as a first-line treatment for adult patients with unresectable or metastatic HER2 positive (IHC 3+ or ISH+) breast cancer, as determined by a locally or regionally approved test, based on the results from the DESTINY-Breast09 trial.

Enhertu (5.4 mg/kg) is approved in more than 100 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic HER2 positive (IHC 3+ or ISH+) breast cancer who have received a prior anti-HER2-based regimen, either in the metastatic setting or in the neoadjuvant or adjuvant setting, and have developed disease recurrence during or within six months of completing therapy based on the results from the DESTINY-Breast03 trial.

Enhertu (5.4 mg/kg) is approved in more than 75 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 low (IHC 1+ or IHC 2+/ ISH-) or HER2 ultralow (IHC 0 with membrane staining) breast cancer, as determined by a locally or regionally approved test, that have progressed on one or more endocrine therapies in the metastatic setting based on the results from the DESTINY-Breast06 trial.

Enhertu (5.4 mg/kg) is approved in more than 100 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy based on the results from the DESTINY-Breast04 trial.

Enhertu (5.4 mg/kg) is approved in more than 80 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic NSCLC whose tumors have activating HER2 (ERBB2) mutations, as detected by a locally or regionally approved test, and who have received a prior systemic therapy based on the results from the DESTINY-Lung02 and/or DESTINY-Lung05 trials. Continued approval in China and the U.S. for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Enhertu (6.4 mg/kg) is approved in more than 90 countries/regions worldwide for the treatment of adult patients with locally advanced or metastatic HER2 positive (IHC 3+ or IHC 2+/ISH+) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the DESTINY-Gastric01, DESTINY-Gastric02 and/or DESTINY-Gastric04 trials.

Enhertu (5.4 mg/kg) is approved in more than 50 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic HER2 positive (IHC 3+) solid tumors who have received prior treatment and have no satisfactory alternative treatment options based on efficacy results from the DESTINY-PanTumor02, DESTINY-Lung01, DESTINY-CRC02, DESTINY-PanTumor03 and/or HERALD trials. Continued approval in China and the U.S. for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

About the Enhertu Clinical Development Program

A comprehensive global clinical development program is underway evaluating the efficacy and safety of Enhertu as a monotherapy or in combination or sequentially with other cancer medicines across multiple HER2 targetable cancers.

About the Daiichi Sankyo and AstraZeneca Collaboration

Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialize Enhertu in March 2019 and Datroway® in July 2020, except in Japan where Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo is responsible for the manufacturing and supply of Enhertu and Datroway.

About the ADC Portfolio of Daiichi Sankyo

The Daiichi Sankyo ADC portfolio consists of nine ADCs in clinical development crafted from ADC technology discovered in-house by Daiichi Sankyo.

The DXd ADC Technology platform of Daiichi Sankyo consists of seven ADCs in clinical development where each ADC is comprised of a monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. The DXd ADCs include Enhertu and Datroway, which are being jointly developed and commercialized globally with AstraZeneca, and ifinatamab deruxtecan (I-DXd), raludotatug deruxtecan (R-DXd) and patritumab deruxtecan (HER3-DXd), which are being jointly developed and commercialized globally with Merck & Co., Inc., Rahway, NJ, USA. DS-3939 and DS3790 are being developed by Daiichi Sankyo.

Additional ADCs being developed by Daiichi Sankyo include DS3610, which consists of an antibody attached to a novel payload that acts as an agonist of STING, and DS1025, which consists of a CD25 directed antibody attached to an immuno-oncology optimized cytotoxic payload.

Ifinatamab deruxtecan, raludotatug deruxtecan, patritumab deruxtecan, DS-3939, DS3610, DS3790 and DS1025 are investigational medicines that have not been approved for any indication in any country. Safety and efficacy have not been established.

About Daiichi Sankyo

Daiichi Sankyo (TSE: 4568) is a global healthcare company committed to becoming a trusted healthcare innovator, transforming the lives of people through its strength in science and technology. The company discovers and develops new standards of care to address diverse medical needs to fulfill its purpose of contributing to the enrichment of quality of life around the world. With a strategic focus on oncology, Daiichi Sankyo is advancing an industry-leading antibody drug conjugate portfolio along with identifying new breakthrough generating technologies to deliver practice-changing medicines to patients, healthcare professionals and society. For more information, please visit www.daiichisankyo.com.

REFERENCES

1 World Health Organization. Global Status Report On Cancer 2026: The Future We Choose Together. Accessed October 2026.

2 World Health Organization. Breast Fact Sheet. Accessed October 2026.

3 Cheng X. Genes. 2024;15(7):903.

4 Tarantino P, et al. Ann Oncol. 2023;34(8):645-659.

5 Mahtani R, et al. Cancers (Basel). 2025;17(11):1848.

6 Geyer CE, et al. N Engl J Med. 2025;392(3):249-257.

7 National Cancer Institute. SEER Cancer Stat Facts: Female Breast Cancer Subtypes. Accessed October 2026.

8 von Minckwitz G, et al. N Engl J Med. 2019;380(7):617-628.

9 Zaborowski AM and Wong SM. BJS. 2023;110(7):765-772.

10 Loibl S, et al. N Engl J Med. 2026;394(9):845-857.

11 Loibl S, et al. ESMO Clinical Practice Guidelines. 2024.

Contacts

MEDIA CONTACTS:
Global:
Jennifer Brennan

jennifer.brennan@daiichisankyo.com
+1 908 900 3183 (mobile)

EU:
Simone Jendsch-Dowé

simone.jendsch-dowe@daiichisankyo.com
+49 (89) 78080 (office)

Japan:
DS-PR_jp@daiichisankyo.com

INVESTOR RELATIONS CONTACT:
DaiichiSankyoIR_jp@daiichisankyo.com